Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05234203 · ClinicalTrials.gov registry record · NA
The Impact of a Polyphenol-Rich Supplement on Epigenetic and Cellular Markers of Immune Age
A NA study of Aging and Inflammation, sponsored by Big Bold Health, PBC.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05234203: Completed NA study of Aging and Inflammation, sponsored by Big Bold Health, PBC.
NCT05234203 is a NA study of Aging and Inflammation that has completed, run by Big Bold Health, PBC. The registered enrollment target is 50 participants, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05234203, a NA study of Aging and Inflammation, has completed, sponsored by Big Bold Health, PBC.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, interventional, single-arm, open-label pilot study of 50 patients to evaluate the effect of a polyphenol-rich nutritional supplement on epigenetic and cellular markers of immune age.
Primary Outcome
Measurement of changes in methylation patterns on DNA related to immune age using the TruAge Biological Age test, which tests for methylation at 850,000 separate locations on DNA
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT HTB Rejuvenate
Study Locations (1)
Washington
- Big Bold Health PBC - Bainbridge Island
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-03-25 |
| Est. Completion | 2022-10-07 |
| Phase | NA |
What the finished NCT05234203 record still lists
NCT05234203 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Aging appearing as the primary indexed condition, and to 1 intervention - of which HTB Rejuvenate is the first listed.
NCT05234203 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT05234203 about?
NCT05234203 is a clinical study titled "The Impact of a Polyphenol-Rich Supplement on Epigenetic and Cellular Markers of Immune Age". This is a prospective, interventional, single-arm, open-label pilot study of 50 patients to evaluate the effect of a polyphenol-rich nutritional supplement on epigenetic and cellular markers of immune age.
What is the current status of trial NCT05234203?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2022-03-25. Estimated completion is 2022-10-07.
What conditions does trial NCT05234203 study?
This clinical trial studies the following conditions: Aging, Inflammation, Immunity Disorders.
What interventions are being tested in trial NCT05234203?
The interventions under investigation include: HTB Rejuvenate (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05234203?
This trial is sponsored by Big Bold Health, PBC, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05234203 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05234203's enrollment target sits among peer trials
50 155th of 262 higher than 105 of 262 other Aging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
Using Nicotine to Reverse Age-related Auditory Processing Deficits
RECRUITING · NA
-
Heterogeneity of Vascular Adaptations to Exercise With Aging in Women and Men
RECRUITING · NA
-
Modulating Neurocognitive Processes of Learning to Trust and Distrust in Aging
RECRUITING · NA
-
Studying the Effects of Digital Interventions on Cognition, Wellbeing, Stress, and Sleep in Older Adults
RECRUITING · NA
-
The GLUCID Study: Effect of Alcohol Reduction and Probiotic Interventions on Cognition and Brain Glucose Metabolism in Normal Aging Adults Who Are High-Risk Alcohol Drinkers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI